Drug Trial Radar · NCT07674290
Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity
Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jan 1, 2023
Primary completion
Dec 31, 2030
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Tom HühneAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Rhythm Pharmaceuticals, Inc.
- First posted
- Jun 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Bardet-Biedl syndrome (BBS) and other rare disorders associated with impairment of the melanocortin-4 receptor (MC4R) pathway are characterized by severe early-onset obesity, hyperphagia, and substantial morbidity. Setmelanotide, an MC4R agonist, is approved in Europe for selected genetic obesity disorders and reimbursed in Germany for eligible patients. This study aims to evaluate the effectiveness, safety, treatment persistence, metabolic outcomes, and patient-reported outcomes of Setmelanotide under real-world conditions. The registry is designed to allow future inclusion of additional MC4R agonists as they become approved and clinically available. The study will primarily be conducted at University Hospital Essen and will collect longitudinal routine clinical data from pediatric and adult patients receiving MC4R agonist therapy according to approved indications.
Conditions
- Bardet Biedl Syndrome (BBS)
- Bardet Biedl Syndrome
- Bardet-Biedl Syndrome (BBS)
- Alstrom Syndrome
Interventions
SetmelanotideDrug
Administration according to approved product labeling and treating physician discretion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in BMI z-scoreTime frame: Baseline to 12/24/36/48/60/72 months
- Impact on lipid profileTime frame: Baseline to 12/24/36/48/60/72 months
- Change in Hepatic Fat AttenuationTime frame: Baseline to 12/24/36/48/60/72 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital Essen, Deparment of Pediatrics II
Essen, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.